Financhill
Back

Y-mAbs Therapeutics Quote, Financials, Valuation and Earnings

Sell
39

YMAB
Y-mAbs Therapeutics

Last Price:
11.76
Seasonality Move:
11.04%

7 Day Trial

ALL ACCESS PASS

$ 7

Y-mAbs Therapeutics Price Quote

$11.76
-0.42 (-3.45%)
(Updated: May 16, 2024 at 6:55 PM ET)

Y-mAbs Therapeutics Key Stats

Sell
39
Y-mAbs Therapeutics (YMAB) is a Sell

Day range:
$12.03 - $12.75
52-week range:
$4.60 - $20.90
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
6.35
P/B ratio:
5.43%

Volume:
267.5K
Avg. volume:
387.1K
1-year change:
18.48%
Market cap:
$538.9M
Revenue:
$84.8M
EPS:
$-0.49

How Much Does Y-mAbs Therapeutics Make?

Is Y-mAbs Therapeutics Growing As A Company?

  • What Is Y-mAbs Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.02%
  • What Is Y-mAbs Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Y-mAbs Therapeutics Stock Price Performance

What Is Y-mAbs Therapeutics 52-Week High & Low?

Y-mAbs Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Y-mAbs Therapeutics?

Is Y-mAbs Therapeutics Cash Flow Positive?

  • What Is YMAB Cash Flow From Operations?
    Cash flow from operations (TTM) is -$17.6M
  • What Is Y-mAbs Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $688K
  • What Is Y-mAbs Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $0

Y-mAbs Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    YMAB return on invested capital is -21.12%
  • What Is Y-mAbs Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -16.67%
  • What Is YMAB Return On Equity?
    ROE is a measure of profitability and is -21.12%

Y-mAbs Therapeutics Earnings Date & Stock Price

Y-mAbs Therapeutics Competitors

Y-mAbs Therapeutics Dividend Yield

Data Unavailable

Y-mAbs Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -17.19%
Revenue: -1.58% -10.3%

Analyst Recommendations

Buy Recommendations: 2
Hold Recommendations: 1
Sell Recommendations: 1
Price Target: 21.33
Upside from Last Price: 75.15%

Major Shareholders

  • How many YMAB shares are owned by institutional investors?
    33M YMAB shares are owned by institutional investors
  • How many YMAB shares are owned by insiders?
    789.9K YMAB shares are owned by insiders